Therefore, current guidelines recommend chromosomal microarray (CMA) and FMR1 testing for the diagnosis of FXS as first-tier tests for individuals with ASD, developmental delay/ID, and/or multiple congenital anomalies [10,11]. Here, FMR1 is linked to fragile X syndrome.